Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies

Trial Profile

Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary)
  • Indications Acute lymphoblastic leukaemia; B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Beijing Doing Biomedical
  • Most Recent Events

    • 01 Sep 2017 Planned End Date changed from 1 Oct 2019 to 1 Apr 2020.
    • 01 Sep 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Apr 2019.
    • 01 Sep 2017 Planned initiation date changed from 1 Jan 2016 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top